Boric acid (BA), an ingredient of many pharmaceutical, cosmetic, and pesticide products, was previously shown to induce reproductive and developmental toxicity in laboratory rodents. In this study, BA (0, 62.5, 125, or 250 mg/kg/day, po) was administered on Gestational Days (GD) 6-19 to New Zealand White rabbits (18-23 pregnant/group). Maternal body weight, food consumption, and clinical condition were monitored at regular intervals throughout gestation. At termination (GD 30), the numbers of uterine implantations, resorptions, dead fetuses, and live fetuses were determined. Fetuses were weighed, and live fetuses examined for external, visceral, and skeletal defects. Maternal food intake decreased during treatment at 250 mg/kg/day and increased at s= 125 mg/kg/day after treatment. Maternal body weight (GD 9-30), weight gain during treatment, gravid uterine weight, and number of ovarian corpora lutea decreased at 250 mg/kg/day. In contrast, maternal corrected gestational weight gain increased at s= 125 mg/kg/day. Maternal liver weight was not affected. Relative (but not absolute) maternal kidney weight increased at 250 mg/ kg/day, and microscopic evaluation revealed no treatment-related renal pathology. At 250 mg/kg/day, prenatal mortality was increased (90% resorptions/litter vs 6% for controls), the proportion of pregnant females with no live fetuses was increased (73% vs 0%), and live litter size was reduced (2.3 fetuses/litter vs 8.8). As a result, there were only 14 live fetuses (6 live litters) available for evaluation in the high-dose group, compared to 153-175 live fetuses (18-23 live litters) in the other groups. The percentage malformed fetuses/litter was increased at 250 mg/kg/day, primarily due to cardiovascular defects in 72% of high-dose fetuses vs 3%
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Boric acid (BA) occurs naturally and is also produced commercially from kernite ore (Woods, 1994; Rainer, 1994) . Boron-containing compounds are used in the manufacture of many consumer products, primarily glass and ceramics, and also as weatherproofing and fireproofing agents, fertilizers, and herbicides. BA powder (99%) is used as an insecticide (U.S. EPA, 1993) , and BA is also a constituent of many cosmetic and medical products intended for human use, antibacterial and antifungal products for horticultural use, and veterinary products (Windholz et al, 1983; Siegel and Wason, 1986; PDR, 1982 PDR, , 1991 .
BA is toxic to humans and animals at sufficiently high doses following oral, systemic, or dermal exposure (Roe ex al, 1972; Weir and Fisher, 1972; Pinto et al, 1978; Arena, 1979; Fail et al, 1991; Treinen and Chapin, 1991; Ku et al, 1991 Ku et al, , 1993a Ku et al, ,b, 1994 . Due to its widespread use, human poisoning by accidental ingestion or dermal contact has been reported (Arena, 1979) . BA is distributed throughout the body and excreted in the urine (Draize and Kelley, 1959; Ku et al, 1991) .
A single dose of boric acid (3000 mg/kg/day, po) on the first day of pregnancy disrupted pregnancy in mice, such that 94% of the embryos failed to undergo blastulation. Lower percentages of embryos were affected at 500-1000 mg/kg/ day (Strongina et al, 1970 , as cited in Beyer et al, 1983 . Despite this initial evidence that high-dose exposure to BA could disrupt embryogenesis in mammals, there remained a lack of developmental toxicity data (Barlow and Sullivan, 1982) until the following series of studies was initiated.
Time-mated Sprague-Dawley-derived (CD) rats were given BA in the diet (0.1, 0.2, or 0.4% on GD 0 to 20 or 0.8% on GD 6 to 15) yielding average intakes of 78, 163, 330, or 539 mg BA/kg body wt/day, respectively . Maternal effects included altered food and/or water intake at 5=0.2% BA, increased relative maternal liver and kidney weights at 5=0.2% BA, decreased gravid uterine weight at 5=0.4% BA, decreased weight gain during treatment and gestation at 5=0.4% BA, and increased corrected body weight gain at 0.4% BA. The percentage malformed fetuses/litter was increased at 0.2, 0.4, and 0.8% BA (8, 50, and 73% malformed compared to 2% in controls). Additional detail regarding morphological findings in rats is presented under Discussion. Prenatal mortality was increased at 0.8% BA (39% of implanted conceptuses vs 4% in controls). Fetal body weight was reduced in all groups (94, 87, 63 , and 46% of control weight, respectively) . The reduction of fetal body weight at 0.1% BA in the diet (76 mg/kg/day) was confirmed, and the no observable adverse effect level (NOAEL) for developmental toxicity in the rat was established at 0.075% BA in the diet (55 mg/kg/day) from GD 0 to 20 (Price et al., 1995b . CD-I mice fed 0.1, 0.2, or 0.4% BA in the diet on GD 0 to 17 ingested considerably higher doses (248, 452, or 1003 mg/kg/day) than rats fed the same concentrations . Mouse dams exhibited mild renal lesions at 5=0.2% BA, increased water intake and kidney weights (0.4% BA), and decreased weight gain during treatment (0.4% B A). Reduction of fetal body weight was dose dependent (94, 89, and 66% of controls), but statistically significant only at 5=0.2% BA. At 0.4% BA, resorptions/litter (19% vs 6% for controls) and malformed fetuses/litter (9% vs 3% for controls) were increased . For additional detail regarding morphological findings in mice, see Discussion.
Based upon the widespread use of BA, a developmental toxicity study of BA in a nonrodent species [as recommended by EPA and FDA (Kimmel and Price, 1990 )] appeared to be warranted. The present study was designed to evaluate maternal condition as well as embryo/fetal growth, viability, and morphological development following administration of BA by gavage to timed-pregnant rabbits during major organogenesis . Maternal and developmental endpoints were comparable to previous developmental toxicity studies of BA in mice and rats .
MATERIALS AND METHODS
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Animals and husbandry. The experimental animals were female New Zealand White rabbits 3 approximately 5 months of age. Male rabbits 5 of the same strain were maintained as breeding stock. Rabbits were individually identified by eartags. Following a 14-day quarantine, ovulation was induced by injection of Pregnyl 6 (0.1 ml/kg, iv) immediately prior to artificial insemination (Bredderman, 1964; Hafez, 1970) on GD 0. The study was performed in two replicates with two consecutive breeding days within each replicate and 34 days between replicates. Females (30/group) were assigned to treatments by stratified randomization so that body weight on GD 0 did not differ among groups within either replicate. The body weight range for individual females on GD 0 was 2690 to 4380 g.
Inseminated females were individually housed in stainless steel cages with mesh flooring.
7 Feed 8 and deionized/filtered water were available ad libitum throughout gestation. Environmental conditions were monitored and controlled by computer.
9 Lights were on from 0700 to 1900 hr for females and from 0700 to 2100 hr for males. Mean temperature was 65°F (range, 64-79°F) and mean relative humidity was 56% (range, 47-89%).
Chemical. Boric acid 9 (BA) was determined to be 99% pure by infrared spectroscopy, and aqueous formulations were stable at room temperature in a 28-day stability study.
10
Treatment. Artificially inseminated New Zealand White does were administered BA (62.5, 125, or 250 mg/kg) or vehicle (distilled/deionized water) once daily on the mornings of GD 6-19. Treatments were administered by gavage (po) using a rubber catheter" fitted with a syringe adapter 12 and attached to a syringe of appropriate volume. Due to the limited solubility of BA in water (55 mg/ml), the dose volume was 5 ml/kg body wt adjusted daily.
Assays (UV/VIS spectrometry) conducted prior to dosing indicated that all formulations were within a range of 94-106% of the theoretical concentrations. Formulations were used within the period of demonstrated stability.
Dose selection. In a previous investigation, all rabbits died following oral administration of 850-1000 mg BA/kg/day for 4 consecutive days. At 800 mg BA/kg, symptoms included anorexia, weight loss, and diarrhea. Minor symptoms (unspecified) were noted at 600-700 mg BA/kg/day, and no toxic signs were reported at =s500 mg BA/kg/day (Draize and Kelley, 1959) . Since published data from rabbits exposed orally to BA were quite limited, preliminary toxicity data were collected in order to select an appropriate dose range for the developmental toxicity study.
In the preliminary toxicity study, nonpregnant female rabbits (2/group) were dosed with BA (0 or 275 mg/kg/day, po) using a dose volume of 5 ml/kg in distilled/deionized water. No deaths or major clinical symptoms occurred following 14 consecutive days of exposure to 275 mg/kg/day. However, average food and water intake (g/animal/day) were depressed during BA exposure (29 and 26% of controls for food and water, respectively). Average weight loss during exposure was -0.05 kg for control females and -1.0 kg for BA females.
Based upon these findings, 250 mg BA/kg/day (GD 6-19) in distilled/ deionized water (5 ml/kg) was selected as the high dose for the developmental toxicity study. It was assumed that this dose would produce some maternal toxicity while allowing survival of all treated females through scheduled necropsy (GD 30). Two lower doses (125 and 62.5 mg/kg/day) were selected as one-half and one-fourth of the high dose, respectively, with the assumption that the lowest dose would be at or near the NOAEL for does.
Evaluations.
Inseminated females were weighed on GD 0, 6-19, 25, and 30. Females were observed daily during and after treatment for clinical signs of toxicity. Maternal food consumption was measured at 2-to 3-day intervals throughout gestation. Surviving females were terminated on GD 30 by injection of Beuthanasia-D Special 13 into the marginal ear vein. The maternal liver, kidneys, and intact uterus were weighed and corpora lutea were counted. Uteri which presented no visible implantation sites were stained with ammonium sulfide (10%) to detect very early resorptions (Salewski, 1964) . Maternal kidneys were bisected, fixed in 10% neutral buffered Formalin, and subsequently sectioned, stained with hematoxylin/eosin, and evaluated histologically.
Live fetuses were dissected from the uterus and euthanized with an ip injection of T-61 Euthanasia Solution 14 or sodium pentobarbital. 15 They were weighed, examined for external morphological abnormalities, including cleft palate, and dissected for visceral examination and determination of sex by a fresh tissue dissection technique (Staples, 1974; Stuckhardt and Poppe, 1984) . Half of the fetuses were decapitated after dissection; the heads were fixed in Bouin's solution and then examined by a freehand sectioning technique (Wilson, 1965) . All fetal carcasses were skinned, cleared, and stained with Alcian blue/Alizarin red S and examined for skeletal malformations and variations (Kimmel and Trammell, 1981; Marr etai, 1988) .
Statistics. The doe or litter was considered the experimental unit for all statistical analyses. General Linear Models (GLM) procedures were applied for the analyses of variance (ANOVA) of maternal and fetal parameters (SAS Institute, 1989a ,b, 1990a . Prior to GLM analysis, an arcsinesquare root transformation was performed on all litter-derived percentage data (Snedecor and Cochran, 1967 ) and Bartlett's test for homogeneity of variance was performed on all data to be analyzed by ANOVA (Winer, 1962) . GLM analysis determined the significance of dose-response relationships and the significance of dose effects, replicate effects, and dose x replicate interactions. When ANOVA revealed a significant (p < 0.05) dose effect, Dunnett's multiple comparison test (Dunnett, 1955 (Dunnett, , 1964 compared BA-exposed groups to control groups. One-tailed tests were used for all pairwise comparisons except maternal body and organ weights and fetal body weight. Nominal scale measures were analyzed by a x 2 test f°r independence and by a test for linear trend on proportions. When a x 2 test showed significant groupwise differences, a one-tailed Fisher's exact probability test was used for pairwise comparisons of control and BA groups.
RESULTS
Maternal effects. Two maternal deaths occurred (one doe at 62.5 mg/kg/day on GD 25; one doe at 125 mg/kg/ day on GD 22), but necropsy did not reveal a definitive cause of death. The condition of the dam at the low dose was suggestive of a gavage error affecting the respiratory system, and the dam at the mid dose had evidence of gastric lesions. Since there was no dose-related incidence of maternal deaths, and no deaths in the high-dose group, there appears to be no connection between maternal death and BA exposure in this study. Among 120 females assigned to this 13 Schering Corp., Kenilworth, NJ. 14 American Hoechst Corp., Somerville, NJ. 15 Barber Veterinary Supply, Inc., Fayetteville, NC. study, 22 (3-7 does/group) were removed for cause as follows: 3 for gavage accidents, 1 for accidental injury, 3 for abortion between GD 20 and 23, and 15 for deviation from ad libitum access to food and/or water (these cases were generally due to the animal dislodging the food hopper or water bottle from the cage or digging the food out of the food hopper). Among the remaining does, the following percentages were confirmed pregnant by uterine examination on GD 30 for the control through high-dose groups: 75% (18/24), 88% (23/26), 87% (20/23), and 96% (22/23).
Pregnant does did not exhibit clinical symptoms attributable to BA toxicity except for vaginal bleeding (i.e., fresh or dried blood in the cage pan, on the legs, in the urine, or near the vagina). The incidence of bleeding was noteworthy at 250 mg/kg/day (2-11 does/day on GD 19-30), and all does with this symptom had no live fetuses on GD 30. Bleeding was not observed in any control females, and in only one female/group at 62.5 and 125 mg/kg/day (Days 20 and 22, respectively; 5-7 live fetuses/litter at term).
At 250 mg/kg/day, maternal food consumption was decreased during the first 10 days of treatment (GD 6 to 15), was comparable among groups during the final days of treatment (GD 15 to 19), was increased during for the period immediately following treatment (GD 19 to 25), and was increased in both the 125 and 250 mg/kg/day groups relative to controls during the final days of gestation (GD 25 to 30) ( Fig. 1; Table 1 ). Maternal body weight (GD 9-30), weight change during treatment, and gravid uterine weight were each decreased at 250 mg/kg/day ( Fig.  2 ; Table 1 ). Maternal weight change throughout gestation was greater than that of controls at 125 mg/kg/day. Corrected maternal weight change was increased at both 125 and 250 mg/kg/day (Table 1) . Maternal relative liver weight was comparable among groups (Table 1) . Relative kidney weight was increased at 250 mg/kg/day, but appeared to be secondary to decreased maternal body weight since absolute kidney weight (data not shown) was comparable across groups. Furthermore, microscopic evaluation of maternal kidney sections failed to provide evidence for any BA-induced renal toxicity (Table 1) .
Embryo/fetal effects. No definitive evidence of developmental toxicity was observed following exposure of pregnant does to either 62.5 or 125 mg/kg/day BA during the period of major organogenesis (Tables 2 and 3 ). At 250 mg/kg/day, developmental toxicity included a high average rate of resorptions and a high percentage of does with complete prenatal loss (Table 2 ). In contrast, the incidence of late fetal deaths was low in all groups (=s2.8%/litter) and showed no systematic relationship to BA exposure (data not shown). Average fetal body weight/litter was 92% of controls at the high dose, but this difference did not reach statistical significance, in part due to the small sample size for this parameter (only 6 litters survived to GD 30 at the high dose, compared to 18-23 litters in the other groups). The overall incidence of malformed fetuses/litter was increased at 250 mg/kg/day BA, but not at 62.5 or 125 mg/ kg/day (Table 2 ). Even though there was an unusually high background incidence of cleft sternum (Table 3) , this did not in any way obscure the identification of treatment-related developmental effects in this study. For reference, when cleft sternum was included in the calculations, the overall incidence of malformed fetuses was 25.2% (40/159), 28.6% (50/ 175), 34.6% (53/153), and 78.6% (11/14) for the control through high-dose groups, respectively. When cleft sternum was excluded from the calculations, the overall incidence of malformed fetuses was 8.8% (14/159), 9.7% (17/175), 11.8% (18/153), and 78.6% (11/14). When malformations were analyzed by general class, the percentage fetuses/litter with external or visceral malformations was increased at the high dose, but the incidence of skeletal malformations was comparable to that of controls (Table 2) .
External malformations were observed with the following incidence among individual fetuses in the control through high-dose groups, respectively: 0.6% (1/159), 1.1% (2/175), 0.7% (1/153), and 14.3% (2/14) ( Table 3) . Although the overall incidence of external malformations was increased at the high dose of BA, distinctive dose-response patterns for individual malformations were not observed (Table 3) . Two fetuses were found to have multiple anatomical defects (major and minor), but in the absence of a dose-response relationship. Thus, one fetus in the control group displayed a domed head, low-set ears, cleft palate, microglossia, enlarged gall bladder, clubbed limb with no underlying bone change, and bilateral full rib on lumbar I. Another fetus in the mid-dose group showed a similar range of defectsdomed head, low-set ears, cleft palate, micrognathia, microglossia, and clubbed limb with no underlying bone change.
The incidence of fetuses with visceral malformations was 8.2, 6.3, 7.8, and 78.6% in the control through high-dose groups (Table 3) . Malformations of the cardiovascular (CV) system (great vessels and heart) were observed with the greatest frequency, and their incidence was significantly increased at the high dose (Table 2) . CV malformations with an elevated incidence included interventricular septal defect in 0.6, 1.7, 1.3, and 57% of the fetuses examined (control through high-dose, respectively); enlarged aorta in 0, 0.6, 0.7, and 36% of fetuses examined; papillary muscle malformations in 3, 2, 4, and 14% of fetuses examined; and double outlet right ventricle (pulmonary artery and aorta both arising from the right ventricle) in 0, 0, 0, and 14% of fetuses examined (Table 3 ). The gallbladder was the only other 46.4 ± 1.5 26.6 ± 2.2** 44.9 ± 2.2 41.9 ± 1.6**° Includes all dams pregnant at euthanization; mean ± SEM. * Maternal gestational and corrected weight gains and relative organ weights were calculated using body weight at the time of euthanization. c Weight gain during gestation minus gravid uterine weight. "* Renal tubular regeneration (minimal). In addition, one dam in the low-dose group showed minimal mineralization of the renal tubules; one dam in the mid-dose group showed mild, multiple subcapsular cysts.
* p < 0.05, linear trend. ** p < 0.05, Dunnett's test.
visceral organ which displayed changes in malformation incidence potentially associated with BA exposure. The incidence of enlarged gallbladder decreased with increasing dose, while the incidence of agenesis increased (Table 3) .
The incidence of fetuses with skeletal malformations (all types) was comparable across treatment groups, i.e., 19, 22, 29, and 29%. The incidence of skeletal malformations among study controls (19%) was noticeably higher than that for historical controls (36/912 or 4%) from the same species/ strain in our laboratory (see NTP, 1991) . This was due primarily to the high incidence of cleft sternum which is presumed to occur due to abnormal midline fusion of the procartilagenous sternal bands. This defect was found in 18% (28/ 159) of the control fetuses in this study vs 2% (18/912) among historical controls. In subsequently conducted studies using the same species/strain in our laboratory, only 0.31% (4/1280) of control rabbit fetuses exhibited cleft sternum. The unusually high incidence of cleft sternum in this study thus represents a transient phenomenon. Although the reasons for this sudden change in background incidence remain obscure, it is clear that the incidence of this defect was not related to BA exposure.
Only two individual skeletal malformations appeared to show an increased incidence in BA-exposed animals (Table  3) : fused sternebrae occurred with an incidence of 1.3, 1.7, 0, and 7%, and fused ribs occurred with an incidence of 0, 0, 1.3, and 7% of fetuses examined. At the high dose, each of these findings occurred in only one fetus and the affected fetuses came from separate litters (i.e., neither defect occurred in more than one high-dose fetus). Thus, the association of fused sternebrae or fused rib with BA exposure was considered equivocal.
The percentage fetuses/litter with anatomical variations was not significantly elevated above controls in any BAexposed group (Table 2 ). The only external variation noted was clubbed limb (without underlying bone change) which never occurred in more than one fetus per group (Table 4) . A wide variety of visceral variations was observed and the two which appeared to show a dose-related incidence involved the same organs that exhibited BA-related malformations. An abnormal number of cardiac papillary muscles was observed in 5, 6, 5, and 50% of fetuses examined, and small gallbladder was observed in 3, 5, 5, and 14% of fetuses examined (Table 4) . Only two skeletal variations were noted and neither of them showed a clear dose-response relationship (Table 4) . Misaligned sternebrae occurred in 1.26, 1.14, 0.65, and 0% of fetuses examined for the control through high-dose groups, respectively. Full extra rib on lumbar I (bilateral or unilateral) occurred in 57, 39, 30, and 43% of fetuses, and rudimentary extra rib on lumbar I (bilateral or unilateral) occurred in 3, 4, 2, and 14% of fetuses examined. Post hoc statistical analysis for individual variations or types of variations was performed only for cardiovascular findings since these showed the only robust association with BA exposure in the present study (Table 2) .
DISCUSSION
Developmental and reproductive toxicity studies of BA in laboratory animals have demonstrated disruption of embryo/ fetal development as well as decreased fertility due to disruption of spermatogenesis following BA exposure (Weir and Fisher, 1972; Heindel et al, 1992; Fail et al, 1991; Treinen and Chapin, 1991; Ku et al, 1991 Ku et al, , 1993a Ku et al, ,b, 1994 Price et al, 1995a . Thus, the finding of developmental toxicity in rabbits exposed to BA during major organogenesis extends previously reported findings in other laboratory species. Developmental and reproductive toxicity studies in laboratory animals have played a pivotal role in recent risk assessments for boron compounds (ECETOC, 1995; IEHR, 1995; Murray, 1995; Smallwood et al, 1995) . The empirical identification of a NOAEL and the statistical derivation of a benchmark dose based on developmental effects in rats (Allen et al, 1996) have been of particular importance in this context since the rat is the most sensitive mammalian species evaluated to date. Rather than attempt to recapitulate the comprehensive reviews presented elsewhere, this discussion is focused on interpretation of the present study in rabbits and a comparison of these results with previously reported studies in rats and mice.
In order to determine whether decreased maternal food intake contributed to adverse developmental outcome at the high dose of BA, our results were compared to those previously reported following feed restriction. Prenatal growth, viability, and morphological development of New Zealand White rabbits (17 mated/group) were not affected by severe food restriction during major organogenesis (15 g/day, GD 7-13, and 25 g/day, GD 14-19) when compared to controls fed ad libitum throughout gestation (250 g of feed/day, GD 0-29; Parker et al, 1986) . In contrast, pregnant New Zealand White rabbits (6-10/group) fed a rationed diet of 150, 60, or 20 g of feed/day (GD 6-20) exhibited increased prenatal mortality (15% at 60 g/day and 46% at 20 g/day, compared to 8% for ad libitum controls consuming 195-248 g of feed/day). At 20 g/day, fetal body weight was 63% of ad libitum controls, but the incidence of external malformations was not affected (visceral and skeletal examinations were not conducted) (Matsuzawa et al, 1981) . In another study, New Zealand White rabbits fed 50 or 15 g/ day (GD 6 to 18) had 14 and 16% resorptions/litter vs 8% for controls which consumed 150 g/day (Clark et al, 1986) . Average fetal body weight was reduced (95 and 87% of control weight, respectively), and an increased incidence of decreased maternal food intake may have been a contributing fetal malformations, including omphalocele, clubbed forefeet, and sternebral anomalies, was noted at 15 g/day. By comparison, rabbits in the high-dose group (this study) consumed 94 g of food/day during treatment and exhibited 90% resorptions/litter (controls consumed 150 g/day and exhibited 6% resorptions/litter). Thus, the control group resorption rate was consistent with the other studies reported, but the incidence of prenatal mortality was disproportionately high in BA-exposed rabbits (this study) relative to rabbits with even greater restriction of food intake (Parker et ai, 1986; Matsuzawa et ai, 1981; Clark et ai, 1986) . Average fetal body weights in BA-exposed groups (this study) were statistically comparable to controls, and the types of malformations (primarily cardiovascular) were dissimilar to those reported after feed restriction in other rabbit studies. Thus, factor, but cannot be solely responsible for the range and severity of adverse developmental effects observed at the high dose of BA.
The background incidence of cleft sternum was unusually high in this study, but was not influenced by BA treatment, per se. Furthermore, cleft sternum was most often observed as an isolated defect and was not consistently associated with other morphological anomalies in individual fetuses. Cleft sternum is a midline defect related specifically to the process of fusion between the procartilagenous sternal bands (Ramirez-Solis et ai, 1993) . In mice, the expression of cleft sternum has a genetic basis (Ramirez-Solis et ai, 1993) , and its induction by chemical agents, such as ethylene oxide, occurs during the early zygotic period (Polifka et ai, 1996) . Based on these considerations, as well as the transient nature of the increase observed in our laboratory, it appears likely that the high background incidence of cleft sternum in this study represents a genetically determined phenomenon. Three mammalian species (rat, mouse, and rabbit) have now been evaluated for developmental toxicity of BA at exposure levels which did not cause maternal mortality. A brief comparison of results across studies is provided below (see also Heindel et al., 1994) , recognizing that differences in experimental design, as well as inherent differences in response across species, may have contributed to the relative outcomes. Although there was overlap in the dose ranges across species, underlying kinetics undoubtedly differed due to differences in the method of administration. Rodents were given BA in feed throughout gestation (GD 0 to 20, rats; GD 0 to 17, mice) or only during organogenesis (GD 6 to 15, rats; Heindel et al, 1992; Price et al, 1995a Price et al, , 1996 . Rats given BA in the diet have been shown to reach steady-state blood and tissue levels of boron by the fourth day of exposure (Treinen and Chapin, 1991) . In contrast, rabbits in this study were given an aqueous solution of BA by gavage once daily during major organogenesis . Further studies are needed to determine whether critical internal exposure parameters are based on area under the curve (AUC) or peak blood and tissue concentrations.
Based upon a comparison of lowest observed adverse effect levels (LOAELs) for developmental toxicity, the rat conceptus was the most sensitive, showing a significant reduction of body weight («94% of control weight) at daily intakes of 2=76 mg/kg/day Price et al, 1996) . In rabbits (this study), fetal weight reduction (92% of control weight) at the high dose did not reach statistical significance possibly due to the small number of litters surviving at this dose. Thus, the developmental LOAEL in rabbits was defined by increased prenatal mortality and malformations at 250 mg/kg/day. The developmental LOAEL in mice (452 mg/kg/day) was based on fetal weight reduction (89% of control weight) . NOAELs for developmental toxicity in these studies were 55 mg/kg/day for rats , 125 mg/kg/day for rabbits (this study), and 248 mg/kg/day for mice .
Susceptibility to BA-induced prenatal mortality showed differences across species despite comparable control values (4-6% of implants resorbed/litter). With regard to prenatal mortality, rabbits were the most sensitive and most severely affected species, experiencing 90% resorptions/litter at 250 mg/kg/day (GD 6-19). The extent of prenatal mortality in rats depended upon both the dose and the period of administration. Rats showed 36% resorptions at 539 mg/kg/day during major organogenesis (GD 6 to 15; Heindel et al., 1992) , but 76% resorptions at 617 mg/kg/day throughout gestation (GD 0 to 20; NTP pilot study). In contrast, mice were relatively resistant showing only 20% resorptions/litter at 1003 mg/kg/day throughout gestation (GD 0 to 17; Heindel et al., 1992) .
As with other developmental endpoints, the induction of malformations by BA also showed species-specific characteristics. In rabbits, the cardiovascular system was clearly a target for morphological defects; 72% of fetuses/litter at 250 mg/kg/day had at least one major cardiovascular malformation (predominantly, interventricular septal defect) compared to only 3% among controls. Because of the high rate of prenatal mortality (90%) at the high dose in rabbits, additional studies using lower doses and/or shorter exposure periods would be useful in characterizing the disruption of cardiovascular morphogenesis. Unlike the rat and mouse, development of the rabbit skeletal system appeared to be relatively insensitive to disruption following BA exposure.
In rats, the incidence of major malformations was elevated at 163, 330, and 539 mg/kg/day BA (8, 50, and 73% malformed/litter) against a control value of 2% malformed . A wide variety of malformations was associated with BA exposure in the rat, including curly and/ or short tail, anophthalmia, microphthalmia, displacement of the eye, cleft sternum, and fused ribs. Other effects on skeletal development included an increased incidence of wavy rib, agenesis or shortening of rib XIII, and a decreased incidence of extra rib on lumbar I Price et al., 1996) . Axial skeletal defects have subsequently been examined in another laboratory following high oral doses of BA (500 mg/kg, bid, on single or multiple days of gestation) in order to characterize critical periods of susceptibility and to provide the foundation for mechanistic research (Narotsky et al., 1995 (Narotsky et al., , 1996 . Cardiovascular malformations in rats were qualitatively similar to those observed in rabbits (i.e., double outlet right ventricle and interventricular septal defect), and the incidence was elevated at the highest BA dose (5% of fetuses vs 0% for vehicle controls). At doses above 280 mg/kg/day, enlargement of the lateral ventricles in rats has been demonstrated following BA exposure in the diet from GD 0 to 20 or GD 6 to 15 Price et al., 1995a) . This morphological finding occurred in the presence of, but was not entirely accounted for by, severe intrauterine growth retardation (Price et al., 1995a) .
The mouse was least sensitive to BA-induction of malformations as well as other developmental effects. The maximum response achieved in mice was 9% malformed fetuses/ litter at 1003 mg/kg/day against a control value of 3%. The most apparent treatment-related morphological changes involved deficient rib development at the thoracolumbar junction, i.e., increased incidence of short rib XIII (classified as a malformation in that study) and decreased incidence of extra rib(s) at lumbar I (classified as a variation). Cardiovascular malformations showed a low incidence («sO.4%) in all groups, and the incidence was not related to BA exposure in mice .
Despite the relative resistance of mice to BA-induced developmental toxicity, the dams were susceptible to induction of renal lesions . Pregnant mice exhibited a dose-related incidence of renal tubular dilatation/regeneration, while pregnant rats and rabbits (this study) failed to show treatment-related microscopic renal lesions at doses that were clearly toxic to the developing conceptus. By inference, maternal renal pathology is not a prerequisite for induction of developmental toxicity after BA exposure.
To summarize this study, decreased food intake and vaginal bleeding associated with pregnancy loss were the principal manifestations of maternal toxicity in New Zealand White rabbits exposed to 250 mg/kg/day BA on GD 6-19. The same dose was associated with severe developmental toxicity, including a high rate of prenatal mortality and malformations. Development of the cardiovascular system was particularly sensitive to disruption. At 125 mg/kg/day, increased maternal food intake and weight gain were not considered adverse. Increased food intake was noted in all three species at one or more doses (Heindel et al., 1994) , and some of these increases were attributable to posttreatment rebound. However, further studies are needed to determine the cause of increased food intake when it is not preceded by a decrease during the treatment period. No definitive evidence of developmental toxicity was observed at 125 mg/ kg/day. The low dose (62.5 mg/kg/day) was clearly nontoxic to both the maternal animal and the developing conceptus. Thus, the maternal and developmental NOAELs for rabbits were considered to be 125 mg/kg/day.
